Senti Biosciences (SNTI)

• Market cap: $25.8M
• 1 day: 3.81%
• 5 days: 9%
• 1 month: -6.57%
• 3 months: -53.51%
• 6 months: -37.91%
• Year to date: -10.82%
• 1 year: -74.45%
• 5 years: -99.02%
• 10 years: -99.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Employees: 48